Summary of the change in the 2.2012 version of chronic myelogenous leukemia guidelined from the 1.2012 version include:
Partial cytogenetic response:prefered added to change therapy to alternate second generation TKL.
Partial cytogenetic response:prefered removed from continued same dose of nilotinib or dasatinib.
Minor or no cytogenetic response:dassatinib 100mg once daily or nilotinib 400mg BID removed and replaced with change therapy to alternate second generatuion TKI.
